PATENT CLAIM ANALYSIS

Application Number: 16131248
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-08
Patent Classification: ["514", "569000"]

Abstract:
The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

Claim (Index 10):
The method of  claim 8 , wherein the infusion solution is administered at a rate of 0.1 ml/min/kg.

Metadata:
- Claim Count in Document: 9.0
- Percentile: 97.0
- Lexical Diversity: 1.67857
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15657933', '14629938', '11012723', '13469854', '15011999']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7614145803916007
- 35 USC 102 Novelty (BERT): 0.5910351778757564
- Combined Prediction Score: 0.7443766401400163
- Mean Citation Score: 367.065984
- Max Citation Score: 550.246
- Similarity Product: 386.3556482321024

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test